To investigate the clinical efficacy of glucagon like peptide-1(GLP-1)receptor agonist and dipeptidyl peptidase-4 (DPP-4) inhibitor on type 2 diabetes mellitus.

A total of 76 patients with type 2 diabetes mellitus admitted to Jincheng General Hospital of Shanxi Province from February 2017 to February 2020 were selected and divided into two groups according to the treatment plan, with 38 cases in each group. The study group was treated with metformin and GLP-1 receptor agonist, and the control group was treated with metformin and DPP-4 inhibitor. the treatment effects, blood glucose indexes and adverse reactions wer retrospectively compared between the two groups.

After treatment, the total effective rate of the study group (94.7%, 36/38) was higher than that of the control group (68.4%, 26/38), χ ²=8.756, P=0.003. After treatment, the fasting blood glucose (FBG), postprandial 2h blood glucose (2hPBG), and glycosylated hemoglobin (HbAlc) of the two groups were lower than those before treatment (P<0.05), and the corresponding values of the study group were lower than those of the control group (t=7.429, 6.305, 2.337, P<0.05). Comparison of the incidence of adverse reactions between the two groups, χ²=0.244, P=0.623.

GLP-1 receptor agonists are superior to DPP-4 inhibitors on type 2 diabetes, and can effectively control blood glucose levels.

Type 2 diabetes mellitus; Glucagon like peptide-1; Dipeptidyl peptidase-4